Abstract We previously demonstrated that methylation of neugogenic differentiation 1 (NEUROD1) gene, a polycomb group target (PCGT) gene is a predictor of response to neoadjuvant chemotherapy in breast cancer. Here, we address the question whether NEUROD1 methylation provides clinical information independent from its expression level, and whether PCGT methylation is homogeneous in breast cancer. We examined: (1) NEUROD1 methylation and mRNA expression in 9 breast cancer cell lines and 63 tumour specimens, (2) DNA methylation in a training set of 55 PCGT genes taken from the centre (TUC) and periphery (TUP) of 15 breast cancer specimens, and compared this with 22 non neoplastic controls, and finally, (3) validated statistically significant genes in an independent set of 20 cases versus 18 controls. 8/9 cell lines demonstrated NEU-ROD1 methylation, whereas, there was only one cell-line that showed NEUROD1 expression. There was no association between methylation and expression in breast tumour specimens, with only 14% exhibiting NEUROD1 expression. Of the 55 PCGT genes analysed, 24% (13/55) were shown to be cancer specific (p \ 0.05) with a receiver-operating-characteristic (ROC) area-under-the-curve (AUC) of [0.7 (range 0.71-0.95). DNA methylation accurately predicted the presence of cancer in both TUC and TUP. DNA methylation of PCGT genes predicts the presence of breast cancer and is not subject to tumour heterogeneity. Further work will reveal if methylation of PCGT genes will serve as a robust means for the clinical detection and assessment of breast cancer.
Introduction
Breast cancer is the most common female cancer. The overall lifetime risk of developing an invasive breast cancer is 10%. Despite progress in early detection and treatment, breast cancer still accounts for the second largest number of cancer related deaths in the western world [1] . Therefore, identification of novel molecular markers with the potential for optimal disease management and improved survival rates is essential.
During the last decade, a huge emphasis has been given to the identification of genetic changes and expression profiles that correlate with clinical characteristics of the disease, in an attempt to discover genetic markers predicting prognosis and response to treatment [2] [3] [4] [5] [6] . Many of these studies have been based on a single sample from within the tumour, assuming that this single region reflects the genetic signature of the whole cancer. However, there are increasing reports of the presence of intra-tumour heterogeneity and its effect on expression profiling in several cancer types [7] [8] [9] [10] [11] [12] [13] , including breast cancer [14, 15] .
Intra-tumour heterogeneity is the result of a multifactorial microenvironment which exhibits a zonal heterogeneity from central to peripheral regions [16] . Studies comparing the central with the peripheral zone have identified expression of different molecules within these regions. In the centre, which is characterised by hypoxic conditions, genes such as vascular endothelial growth factor (VEGF) have been shown to be regulated and molecules such as the matrix metalloproteinases (MMPs) are overexpressed. In the tumour periphery, which is localised at the stromal border, forming the biologically active invasion front and cancer stem cell reservoir, molecules such as E-cadherin have been shown to be down-regulated [17, 18] . Even, for oestrogen (ER) and progesterone receptors (PR), which are the most significant markers in treatment strategies, there is conflicting data with studies also reporting to be differently expressed in different regions within the tumour [19] [20] [21] . This has led to an increased emphasis for the need to study more than one part of the tumour to ensure the generation of accurate and reproducible data, especially as these data are used to guide patient management. Based on these observations we suggest that the problem of intratumour heterogeneity may be overcome by studying DNA based alterations, such as epigenetic changes, specifically DNA methylation, which may not be affected by the zonal microenvironment of the tumour.
Epigenetic modifications, and in particular DNA methylation, is known to be an early event in carcinogenesis and to precede major genetic changes leading to cancer. The main differences between epigenetic and genetic alterations are that the former occuring at a higher frequency, are reversible upon treatment with pharmacological agents, and arise at defined regions within a gene [22, 23] . These characteristics make them an attractive alternative for cancer detection and assessment [24, 25] . Several studies have shown multiple genes to be differently methylated in normal versus tumour tissue [26] [27] [28] [29] . Recently, we and others demonstrated that stem cell polycomb group-target (PCGT) genes are more likely to have cancer specific promoter DNA hypermethylation than non-PCGT genes [30] [31] [32] . Furthermore, we showed that hypermethylation of NEUROD1 within pretreatment core biopsies preferentially discriminated between neoplastic and non-neoplastic breast tissue samples, and was associated with a favourable response to treatment [27] . Given the data showing that expression profiles are affected by intra-tumour heterogeneity, it is essential to establish that the methylation profile of the core biopsy is representative of the entire tumour.
In this study, we initially analysed the expression and DNA methylation profile of NEUROD1 in 9 breast cancer cell lines and 63 frozen breast cancer tissues. Based on the results we postulated that a DNA methylation signature may carry information independently from the expression profile of the tumour. In order to further investigate both the predictive role and homogeneity of PCGT gene methylation in breast cancer, we compared methylation levels using MethyLight, a highly sensitive real-time PCR methylation assay [33] , of PCGT genes in paraffin embedded breast cancer tissue biopsies taken from the central (TUC) and peripheral (TUP) parts of the tumour and compared this with non-neoplastic breast tissue.
Materials and methods

Subjects
The project was jointly approved by the UCL/UCLH Research Ethics Committee, University London College and by the University of Salzburg. The samples were collected at the Department of Pathology, Paracelsus Private Medical University Salzburg (Salzburg, Austria). Clinical and pathologic data were stored in a database in accordance with hospital privacy regulations. For the mRNA analysis, frozen breast tissue samples were collected from 63 patients with breast cancer. The breast cancer specimens were obtained immediately after resection of the breast or lumpectomy, and therefore prior to treatment. The specimens were processed by the pathologist and part of the tissue was pulverized under liquid nitrogen and stored at -70°C. Clinicopathological features of these samples have previously been reported [27] . For the PCGT gene methylation analysis, tissue samples were collected from postmenopausal women undergoing surgery for ER?ve breast cancer or benign breast changes. Core biopsies were dissected from the centre of pT1 and pT2 invasive ductal carcinoma and from the peripheral cancer stromal border, as shown in Supplementary S1. Relevant tissue areas from tumours at least 1 cm in diameter were selected on Haematoxylin and Eosin (H&E) slides and used to guide dissection from the paraffin block. For DNA extraction, 3 mm diameter core punches were used. The samples were a priori separated into two sets: training and validation. Although grading (p = 0.073) and sentinel status (p = 0.072) p values almost reached statistical significance, no other clinicopathological feature demonstrated significant differences (p values \ 0.05) between the two sets as shown in Table 1 .
Cell-lines, culture conditions and reagents
Human breast cancer cell lines BT-20, ZR-75-1, MCF7, MDA-MB-231, T-47D, and SK-BR-3 were obtained from the American type culture collection (ATCC) and cultured according to the recommended guidelines. The following cell lines were generously provided: HBL-100 from NE Hynes, F Miescher Institute, Basle, Switzerland and Hs 578T from GC Buehring, School of Public Health, Berkley, CA, USA and were cultured in Dulbecco's modified eagle medium (DMEM; Gibco Invitrogen Corporation, Lofer, Austria) containing 10% fetal bovine serum (Biochrom AG, Berlin, Germany).
RNA isolation and RT-PCR
Total cellular RNA was extracted from the tumour specimens using the acid guanidium thiocyanate-phenolchloroform method, and reverse transcription was performed as previously described [34, 35] . Primers and probes for NEUROD1 RT-PCR analysis were purchased from Applied Biosystems (Applied Biosystems Assay ID: Hs00159598_m1). Primers and probes for the TATA boxbinding protein (TBP; a component of the DNA-binding protein complex TFIID as endogenous RNA control) were used according to Bieche et al. [36] . Real-time PCR was performed using an ABI Prism 7900HT Detection System (Applied Biosystems, Foster City, CA). The standard curves were generated using serial dilutions of standard cDNA derived from the HBL-100 breast carcinoma cellline.
DNA isolation, bisulphite modification and analysis of DNA methylation DNA was extracted using the QIAGEN/QIA-amp Tissue kit as previously described [27] . Specific criteria were set up to select the eligible samples to perform for the analysis as follows: The quality of the genomic DNA was checked by two methods: (1) quantification and (2) real-time PCR using three housekeeping genes collagen 2A1 (COL2A1), b-actin (ACTB) and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) (primer sequences are provided in Supplemental Table S1 ). The samples that had sufficient DNA for the purpose of analysis and a mid-exponential cycle threshold (Ct) value of \36, were included in the study (data not shown). The eligible samples were bisulphite modified based on the manufacturer's instructions (Zymo Research, Orange, CA) and MethyLight analysis was performed as described previously [27] . The specificity of the reactions for methylated DNA was confirmed using SssI (New England Biolabs, UK) treated human white blood cell DNA (heavily methylated). The percentage of fully methylated molecules at a specific locus, as defined by percentage of methylated reference (PMR), was calculated by dividing the GENE:COL2A1 ratio of a sample by the GENE:COL2A1 ratio of the SssItreated human white blood cell DNA, and multiplying by 100. The analysis was performed blinded, and cases and controls were randomly mixed during bisulphite treatment and realtime PCR. The concentration of bisulphite modified DNA (assessed by the level of the reference gene COL2A1) was the same between cases and controls (data not shown). A detailed list of the nucleotide sequences for MethyLight primers and probes in the promoter or 5 0 end region for all analysed loci is provided in supplemental Table S1 .
Statistics
Statistical analysis was carried out using a computer assisted program-SPSS version 12.0.1, Chicago, IL. For both training and validation sets, for each gene the percent of non-zero results, the median and the p values from the Mann-Whitney test, were calculated. The genes in both training and validation sets were also assessed using receiver-operating-characteristic (ROC) curves and the area-under-the curve (AUC) value. When a gene was denoted with a 'reverse decision rule' this meant that the higher the methylation value the more likely the subject would be a control rather than a case. In order to assess if there is a difference between the TUC and TUP groups, a non-parametric paired test (Wilcoxon rank test) was carried out comparing the rank order of values for TUC versus TUP. Spearman correlation analysis was performed in order to examine any association between the two zones, tumour taken from the centre and periphery.
Results
NEUROD1 methylation does not correlate with NEUROD1 mRNA expression
Based on two of our recent studies, we showed that NEU-ROD1 was one of the best discriminators between breast cancer and non neoplastic tissue samples [30] and that methylated NEUROD1 promoter could be a good predictive marker for chemosensitivity in breast cancer [27] . Since cancer specific methylation of some of the PCGT genes, such as myogenic differentiation 1 (MYOD1) and neugogenin 1 (NEUROG1) has been shown not to be associated with expression in epithelial cancers [30] , we wanted to investigate the association of the methylation and expression profile of NEUROD1 in breast cancer. Therefore, we analysed and compared NEUROD1 methylation and NEUROD1 mRNA expression in a panel of nine human breast cancer cell lines. As it is illustrated in Figure 1 , from the 9 tested cell lines only 1 expressed NEUROD1 whereas, NEUROD1 methylation was observed in 8 out of 9 cell lines. To further examine this observation, we analysed NEU-ROD1 expression and methylation of 63 frozen breast cancer tissue samples. The experiments were performed in triplicate and, when at least two signals of the analysis had given a negative value, the expression was considered as zero. As is seen in supplemental Table S3 , the majority of the cases, 54/63 (85.7%) did not express NEUROD1 in contrast to NEUROD1 methylation, which was detected in all cases with a PMR value ranging from 0.05 to 633.
PCGT genes can predict the presence of breast cancer
In order to further investigate the methylation level changes of the PCGT genes in breast cancer we analysed a sample set consisting of TUC and TUP tissues from 35 postmenopausal women with ER?ve breast cancer and compared these with non neoplastic breast tissue from 40 postmenopausal women who had undergone surgery for benign breast changes. The samples were divided into a training set consisting of 15 cases and 22 controls, and a validation set of 20 cases and 18 controls.
In the training set, we examined methylation of 55 PCGT genes in 14 TUC and 15 TUP samples and 22 controls. 24% (13 out of 55) of the genes analysed were cancer specific (p \ 0.05), being more frequently methylated in tumour samples when compared with non neoplastic tissues as illustrated in Table 2 . To test the hypothesis that the selected genes are cancer predictors, we assessed them by ROC analysis as seen in Table 3 . In this table, for both TUC and TUP groups, the p values given reflect whether the AUCs are significantly different from 0.5 (a straight line from bottom left to top right corners, implying a decision rule no better than chance). The predictive value of the 13 genes was statistically significant showing an AUC range of 0.667-0.930 for the TUC samples and 0.714-0.955 for the TUP samples.
To further validate these findings, we analysed in an independent validation set consisting of 19 TUC, 20 TUP samples and 18 controls, the 13 PCGT genes from the training set that had a p \ 0.05 in the Mann-Whitney analysis for both TUC and TUP. All 13 genes (Table 4) were confirmed and were shown to be statistically significant in the validation set (p \ 0.05). We calculated the predictive potential of these 13 genes by ROC analysis as it is illustrated in Table 5 . Interestingly, even though the sample size is low, the results were consistent and the same panel of genes that were shown to be statistically significant with the Mann-Whitney test also had a statistically significant AUC value (p \ 0.05).
DNA methylation of PCGT genes is not affected by intra-tumour heterogeneity Even though we show methylation levels of specific genes to be comparable between selected TUC and TUP tissue samples in both the training and validation sets, there were also some genes that demonstrated differential methylation levels between the two tumour zones. This was true not only for both cancer specific genes (genes that were shown to be specifically methylated in the breast tumour tissue when they were compared with the controls) but also for the genes that were shown to be non-specifically methylated in cancer. In order to verify these results we performed non-parametric paired test for the genes one by one. The p values for each gene, suggested that there was no difference in the methylation level between the two zones within the tumour for cancer specific genes (Table 6 ) and non-cancer specific genes (supplemental Table S4 ). In order to investigate whether there is any correlation between the two different zones, we performed Spearman correlation analysis. The analysis showed 4 out of the 13 genes to be positively correlated in both the training and validation for the two different zones of the tumour (Table 6 ).
Discussion
Over the last few years, the role of DNA methylation in cancer has been the subject of many studies and it is TUC Tumour taken from the centre, TUP Tumour taken from the periphery, AUC Area under the curve, CI Confidence interval The performance of each gene as a predictor of breast cancer was assessed using ROC curves and the AUC value. The genes were ordered according to the rank of the p value for the test of TUC and TUP versus control. Significance required a p value of less than 0.05 * 'Reverse decision rule' applied means that the higher the methylation value, the more likely the subject is a control rather than TUC or TUP breast cancer case generally accepted that methylation of gene promoters is associated with gene silencing. However, as accumulating evidence suggests that DNA methylation can occur at loci without an effect on gene expression, we wanted to investigate the correlation between NEUROD1 methylation and expression. Based on this analysis no association between DNA methylation and gene expression was found. These data are in agreement with previous reports suggesting that PCGT genes with tumour-specific promoter DNA methylation are not normally expressed in the ROC Receiver operating characteristic, AUC Area under the curve, TUP Tumour taken from the periphery, TUC Tumour taken from the centre, CI Confidence interval The performance of each gene as a predictor of cancer was assessed using ROC curves and the AUC value. The significant assessment required a p value of less than 0.05. The genes were ordered according to the rank of the p value for the test of TUC and TUP versus control * 'Reverse decision rule' applied means that the higher the methylation value, the more likely the subject is a control rather than TUC or TUP cancer case
epithelium of the tumour. It also provides further evidence on our previous published data that DNA methylation of PCGT genes in cancer may result in a residual stem-cell memory rather than a selective pressure for silencing these particular genes during carcinogenesis [30] . Therefore, based on the following three observations: (1) there is no relationship between NEUROD1 methylation and expression levels (2) lack of NEUROD1 expression in the majority of the samples tested and (3) published findings that methylation of PCGT genes is a promising target for marker identification [27, [30] [31] [32] , we wanted to further examine the predictive role of these genes in breast cancer and to examine whether they are affected by intra-tumour heterogeneity. MethyLight analysis of PCGT genes identified a constant panel of genes to be methylated in both central and peripheral tumour samples compared with controls, and non-parametric paired analysis indicated that there was no statistical significant difference between the methylation levels of the two zones within the cancer. This was true for both breast cancer specific genes and genes that were not specifically methylated in cancer. In order to investigate whether there is an association between the methylation changes observed in the two different tumour tissues, we performed correlation analysis showing 4 out of 13 genes to be positive associated.
NEUROD1 was one of the genes that did not show statistically significant differences in the methylation levels between TUC and TUP, suggesting it is homogeneously methylated within the tumour. This is an important finding as it further supports our previous report that NEUROD1 methylation could be a good predictive marker in breast cancer as it is not affected by intra-tumour heterogeneity [27] . Moreover, this study provides further evidence for paired-like homeodomain transcription factor 2 (PITX2) which has been shown by Harbeck et al. [37] to be a good biomarker for breast cancer hormone therapy treatment and, having performed analysis of several different tissue sections, has also shown a low variability in methylation measurements.
To our knowledge there is no other study that has examined breast cancer intra-tumour heterogeneity and its effect on DNA methylation changes. In contrast, there are two studies analysing expression modifications in correlation to intra-tumour heterogeneity. Both were carried on micro-dissected tumour cells rather than core biopsies. The first study by Aubele et al. [14] confirmed heterogeneity by comparative genomic hybridization. The second study by Zhu et al. [15] described expression heterogeneity in sections that were obtained from morphologically dissimilar regions, one from the centre containing invasive breast tumourigenic cells, and the other from the periphery containing ductal carcinoma in situ (DCIS). The differences in the expression profile described in this study could be attributed to the different type of cells analysed i.e. comparing invasive with non-invasive cells. Our finding that methylated PCGT genes provide reliable data irrespective of sampling topography, suggests that methylation analysis of these genes could hold great potential for improving breast cancer management. In addition, we have also demonstrated that the technology for methylation analysis can be easily applied in clinical routine as only a core biopsy would be required instead of purified cell population of cells. Our results are in contrast to reports of DNA methylation changes of different candidate genes in other cancer types which have been shown to be affected by intratumour heterogeneity. In melanoma, when methylation changes and expression status of suppressor genes were analysed, tissue taken from the centre of the tumour found to represent the whole tumour more accurately than the tissue from the periphery [38, 39] . A more recent study of ovarian cancer suggested that both inter-and intra-tumour heterogeneity are allied with NY-ESO-1 expression, which was correlated with promoter and global DNA-methylation alterations when micro-dissected cells were analysed [40] . Further studies are required before it can be determined whether these changes are cancer or gene specific.
In this study, we have identified and confirmed in the validation set, 13 PCGTs that can predict breast cancer. This includes the first report of hypermethylation of the transmembrane protein with EGF-like and two follistatin-like domains 2 (TEMFF2), the proenkephalin (PENK), glutamate decarboxylase-1 (GAD1) and cellular retinoic acid binding protein 1 (GRABP1) genes in breast cancer. Even though the role of TMEFF2 gene methylation has been observed in other types of cancer such as colorectal, bladder [41, 42] and gastric adenocarcinomas [43] , there are no reports for breast cancer. PENK gene expression has been shown to be down regulated in prostate and bladder cancer using, expression profiling [44] . Methylation of GAD1 has not been previously shown to be associated with cancer and CRABP1 methylation was only reported in association with colon [45] and ovarian [46] cancer. In contrast, there are reports of an association between methylation of PITX2 and metallothionein 1A (MT1A) with breast carcinogenesis, further validating the data presented [37, 47] .
Interestingly, 6 of the 13 methylated loci we identified are genes belonging to the homeobox (HOX) domain. These genes are known to control normal development and differentiation of many multi-cellular organisms [48] . For more than a decade the role of the HOX domain in carcinogenesis has also been highlighted. An example is HOXB7 which has been implicated as an oncogene and is known to increase the expression of basic fibroblast growth factor (bFGF) in melanoma [49] . Indeed, previous data has confirmed that HOX gene cluster methylation is a common feature in cancer [50] including breast cancer [25, 51] . In the search for more specific and sensitive markers, a recent study by Fiegl et al. [52] has shown that HOXA11 is methylated in ovarian cancer and a marker indicating poor prognosis.
It is worth mentioning despite the small sample size used in this study, our results are consistent and identified cancer specifically methylated genes characterized by high AUC values indicating a high sensitivity and specificity compared with studies that have used larger sample sizes [25] .
For future work we plan to investigate methylation profiles of metastatic specimens compared with matched primary tissues in order to examine whether DNA methylation of PCGT genes is homogeneous in breast cancer metastases. A recent study by Wu et al. [53] demonstrated that samples taken from a patient's primary breast carcinoma and their metastatic breast cancer are characterized by extensive expression heterogeneity. The study confirmed that ER and/or PR status characterizing the primary cancer may be lost in the metastatic carcinoma. This observation is important as the metastasis will not be hormone sensitive as its primary carcinoma resulting in resistance to the therapy. Interestingly the methylation signature of the primary tumour tissue compared with the metastatic specimen was similar, with the latter only exhibiting a higher intensity of methylation.
This is a proof of principle study demonstrating for the first time that methylation of PCGT genes is unaffected by intratumour heterogeneity within a set of breast cancer samples. These findings suggest that methylation of specifically identified PCGT genes may present a more robust means with which to guide breast cancer management, particularly in instances when only small core biopsies are available for assessment. Further investigation of epigenetic intra-tumour heterogeneity within breast cancer, as well as other cancer types is necessary; nonetheless evidence is beginning to accumulate in recognition of the potential of DNA methylation markers in cancer assessment and treatment.
